Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile ALK rearrange
Therapy Deulorlatinib
Indication/Tumor Type lung non-small cell carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK rearrange lung non-small cell carcinoma sensitive Deulorlatinib Phase I Actionable In a Phase I/Ib trial, Deulorlatinib (TGRX-326) treatment demonstrated safety in non-small cell lung cancer patients harboring an ALK rearrangement and led to an objective response rate (ORR) of 71.4% (10/14) and disease control rate (DCR) of 100% in Xalkori (crizotinib)-pretreated patients, an ORR of 87.9% (29/33) and DCR of 97.0% (32/33) in TKI-naive patients, and an ORR of 38.1% (37/97) and DCR of 81.4% (79/97) in patients pre-treated with second-generation TKIs (PMID: 39551469; NCT05441956). 39551469
PubMed Id Reference Title Details
(39551469) Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial. Full reference...